rabeprazole has been researched along with Peptic Ulcer in 65 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to clarify the efficacy of rabeprazole for preventing peptic ulcer, esophagitis, and gastrointestinal symptoms associated with LDA." | 9.16 | Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. ( Azuma, T; Fujisawa, T; Fujita, T; Hayakumo, T; Inokuchi, H; Kawai, T; Kutsumi, H; Kuwayama, H; Matsubara, Y; Miyaji, H; Murakami, M; Sanuki, T; Terao, S; Yamazaki, Y; Yoshida, S, 2012) |
| " As a result, clopidogrel's incidence of peptic ulcer disease (PUD) and ulcer bleeding is lower than aspirin's." | 9.15 | Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. ( Chen, LC; Hou, MC; Huang, KW; Lee, FY; Lee, SD; Leu, HB; Li, CP; Lin, HC; Lu, CL; Luo, JC, 2011) |
| "Low-dose rabeprazole 10 mg has a similar efficacy for the healing rapidity of active peptic ulcer disease and symptom improvement compared with standard-dose omeprazole 20 mg." | 9.12 | Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. ( Baik, SK; Jee, MK; Ji, S; Kim, HS; Kim, JW; Kwon, SO; Lee, DK; Park, KW; Song, JS; Uh, Y, 2006) |
| "To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents." | 9.11 | [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients]. ( Lin, SR, 2005) |
| " pylori-positive patients with peptic ulcer disease were received rabeprazole 10 mg bid, amoxicillin 1,000 mg bid and clarithromycin 500 mg bid for a week." | 9.10 | [A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer]. ( Choi, BK; Chung, JM; Jang, YS; Lee, SH; Lee, YJ; Park, ET; Seol, SY; Yang, SY, 2003) |
| " pylori-infected peptic ulcer patients were randomly assigned to 1 of 3 groups: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days), RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days), and OAC7 (omeprazole 20mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)." | 9.10 | Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. ( Chen, JH; Chen, TJ; Lee, SC; Wang, GM; Yang, KC, 2003) |
| "In this randomised, double-blind, multicentre study, conducted at 27 European sites, the efficacy and safety of rabeprazole and omeprazole were compared in patients with erosive or ulcerative gastro-oesophageal reflux disease (GERD)." | 9.09 | Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 9.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| "Kangfuxin (KFX), a well-known Chinese patent medicine which extracted from Periplaneta americana, is widely used as an adjuvant in the treatment of peptic ulcers (PUs) with proton pump inhibitors (PPIs) such as rabeprazole, in China." | 9.05 | Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis. ( Gao, F; Lin, M; Luo, R; Shi, J; Sun, J; You, J; Zhang, C; Zhang, J; Zhang, M; Zhang, S, 2020) |
| "The study was intended to develop a new intra-gastric floating in situ microballoons system for controlled delivery of rabeprazole sodium and amoxicillin trihydrate for the treatment of peptic ulcer disease." | 7.83 | Stomach specific polymeric low density microballoons as a vector for extended delivery of rabeprazole and amoxicillin for treatment of peptic ulcer. ( Agrawal, GP; Amin, MCIM; Choudhary, S; Jain, A; Kesharwani, P; Mishra, V, 2016) |
| " We aimed to clarify the efficacy of rabeprazole for preventing peptic ulcer, esophagitis, and gastrointestinal symptoms associated with LDA." | 5.16 | Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. ( Azuma, T; Fujisawa, T; Fujita, T; Hayakumo, T; Inokuchi, H; Kawai, T; Kutsumi, H; Kuwayama, H; Matsubara, Y; Miyaji, H; Murakami, M; Sanuki, T; Terao, S; Yamazaki, Y; Yoshida, S, 2012) |
| " As a result, clopidogrel's incidence of peptic ulcer disease (PUD) and ulcer bleeding is lower than aspirin's." | 5.15 | Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. ( Chen, LC; Hou, MC; Huang, KW; Lee, FY; Lee, SD; Leu, HB; Li, CP; Lin, HC; Lu, CL; Luo, JC, 2011) |
| "Two hundred and forty Chinese with peptic ulcer disease were randomly assigned to the following regimens: amoxicillin and clarithromycin together with omeprazole (OAC) or rabeprazole (RAC)." | 5.14 | The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. ( Hu, YM; Li, QS; Mei, Q; Xu, JM; Zhang, L, 2010) |
| "Low-dose rabeprazole 10 mg has a similar efficacy for the healing rapidity of active peptic ulcer disease and symptom improvement compared with standard-dose omeprazole 20 mg." | 5.12 | Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. ( Baik, SK; Jee, MK; Ji, S; Kim, HS; Kim, JW; Kwon, SO; Lee, DK; Park, KW; Song, JS; Uh, Y, 2006) |
| "To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents." | 5.11 | [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients]. ( Lin, SR, 2005) |
| " pylori-infected peptic ulcer patients were randomly assigned to 1 of 3 groups: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days), RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days), and OAC7 (omeprazole 20mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)." | 5.10 | Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. ( Chen, JH; Chen, TJ; Lee, SC; Wang, GM; Yang, KC, 2003) |
| " pylori-infected peptic ulcer patients were randomly treated with either rabeprazole (10 mg b." | 5.10 | Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. ( Habu, Y; Hayakumo, T; Inokuchi, H; Kawabata, H; Kawai, K; Kimoto, K; Kiyota, K; Kobayashi, M; Kutsumi, H; Mizuno, S; Nakajima, M; Oyasu, K; Tomioka, H, 2003) |
| " pylori-positive gastritis or peptic ulcers were randomly assigned to receive 30 mg lansoprazole twice daily (LAC group), 10 mg rabeprazole twice daily (RAC20 group), or 20 mg rabeprazole twice daily (RAC40 group), with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week." | 5.10 | Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. ( Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM, 2003) |
| " pylori-positive patients with peptic ulcer disease were received rabeprazole 10 mg bid, amoxicillin 1,000 mg bid and clarithromycin 500 mg bid for a week." | 5.10 | [A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer]. ( Choi, BK; Chung, JM; Jang, YS; Lee, SH; Lee, YJ; Park, ET; Seol, SY; Yang, SY, 2003) |
| "In this randomised, double-blind, multicentre study, conducted at 27 European sites, the efficacy and safety of rabeprazole and omeprazole were compared in patients with erosive or ulcerative gastro-oesophageal reflux disease (GERD)." | 5.09 | Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 5.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| "Kangfuxin (KFX), a well-known Chinese patent medicine which extracted from Periplaneta americana, is widely used as an adjuvant in the treatment of peptic ulcers (PUs) with proton pump inhibitors (PPIs) such as rabeprazole, in China." | 5.05 | Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis. ( Gao, F; Lin, M; Luo, R; Shi, J; Sun, J; You, J; Zhang, C; Zhang, J; Zhang, M; Zhang, S, 2020) |
| " Rabeprazole is a potent and irreversible inhibitor of H(+)/K(+)-ATPase gastric pump, and it is indicated for the treatment of gastroesophageal reflux disease, Zollinger Ellison syndrome, duodenal and gastric ulcers and for the eradication of Helicobacter pylori in combination with antibiotics." | 4.88 | Rabeprazole for the treatment of acid-related disorders. ( Marelli, S; Pace, F, 2012) |
| "Rabeprazole (Aciphex, Alfence, Pariet) is a proton pump inhibitor (PPI) used for the treatment of adults with conditions requiring a reduction of gastric acid secretion such as erosive or ulcerative gastro-oesophageal reflux disease (GORD), non-erosive reflux disease (NERD), duodenal and gastric ulcers, and pathological hypersecretory conditions including Zollinger-Ellison syndrome (ZES)." | 4.85 | Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. ( Baldwin, CM; Keam, SJ, 2009) |
| " Pharmacodynamic results have also suggested that rabeprazole may be better suited than omeprazole as on-demand therapy for symptomatic gastro-oesophageal reflux disease." | 4.82 | Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. ( Horn, J, 2004) |
| "The study was intended to develop a new intra-gastric floating in situ microballoons system for controlled delivery of rabeprazole sodium and amoxicillin trihydrate for the treatment of peptic ulcer disease." | 3.83 | Stomach specific polymeric low density microballoons as a vector for extended delivery of rabeprazole and amoxicillin for treatment of peptic ulcer. ( Agrawal, GP; Amin, MCIM; Choudhary, S; Jain, A; Kesharwani, P; Mishra, V, 2016) |
| "To investigate whether or not CYP2C19 genotype status is associated with cure rate for Helicobacter pylori infection in patients with cirrhosis and peptic ulcer, achieved with 2 weeks of triple therapy with rabeprazole, amoxicillin and clarithromycin." | 3.76 | Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer. ( Lay, CS; Lin, CJ; Lin, JR, 2010) |
| " For the rate of adverse events, there was no significant difference among all the PPIs, vonoprazan, and placebo." | 2.82 | Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis. ( Chen, J; Deng, W; Xie, Z; Yang, S, 2022) |
| "Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category." | 2.71 | Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. ( Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansia, C; Savarino, V; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| " We determined the therapeutic effects of sofalcone and polaprezinc when combined with rabeprazole, amoxicillin and clarithromycin for Helicobacter pylori infection." | 2.71 | Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. ( Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Ohnita, K; Wen, CY, 2005) |
| " One of the key distinguishing features of rabeprazole was related to the lesser involvement of polymorphic metabolism in its pharmacokinetic disposition." | 2.58 | Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview. ( Dash, RP; Rais, R; Srinivas, NR, 2018) |
| "Rabeprazole is a newer generation proton pump inhibitor that suppresses the gastric proton pump and acid secretion more rapidly than does omeprazole, lansoprazole or pantoprazole." | 2.42 | Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment. ( Miner, P, 2004) |
| "Rabeprazole is a proton pump inhibitor with antisecretory properties." | 2.40 | Rabeprazole. ( Faulds, D; Prakash, A, 1998) |
| "Rabeprazole was similar to omeprazole and superior to placebo in both maintenance of healing and prevention of symptoms in patients with healed GERD in 1-year studies." | 2.40 | Rabeprazole: a review of its use in acid-related gastrointestinal disorders. ( Langtry, HD; Markham, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.15) | 18.2507 |
| 2000's | 44 (67.69) | 29.6817 |
| 2010's | 13 (20.00) | 24.3611 |
| 2020's | 4 (6.15) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, KS | 1 |
| Shah, AK | 1 |
| Bariwal, J | 1 |
| Shelke, SM | 1 |
| Kale, AP | 1 |
| Jagtap, JR | 1 |
| Bhosale, AV | 1 |
| Kinoshita, Y | 2 |
| Kato, M | 1 |
| Sugizaki, K | 1 |
| Ikeuchi, S | 1 |
| Yang, S | 3 |
| Deng, W | 3 |
| Xie, Z | 3 |
| Chen, J | 3 |
| Tang, Y | 1 |
| Tang, G | 1 |
| Pan, L | 1 |
| Zhu, H | 1 |
| Zhou, S | 1 |
| Wei, Z | 1 |
| Lin, M | 1 |
| Zhang, S | 1 |
| Zhang, M | 1 |
| Shi, J | 1 |
| Zhang, C | 1 |
| Luo, R | 1 |
| You, J | 1 |
| Sun, J | 1 |
| Zhang, J | 1 |
| Gao, F | 1 |
| Liu, MK | 1 |
| Wu, IC | 1 |
| Lu, CY | 1 |
| Kuo, CH | 1 |
| Yu, FJ | 1 |
| Liu, CJ | 1 |
| Hsu, PI | 1 |
| Hsu, WH | 1 |
| Su, YC | 1 |
| Chen, A | 1 |
| Wu, DC | 1 |
| Kuo, FC | 1 |
| Chen, JJ | 1 |
| Chung, KH | 1 |
| Lee, DH | 1 |
| Jin, E | 1 |
| Cho, Y | 1 |
| Seo, JY | 1 |
| Kim, N | 1 |
| Jeong, SH | 1 |
| Kim, JW | 2 |
| Hwang, JH | 1 |
| Shin, CM | 1 |
| Choudhary, S | 1 |
| Jain, A | 1 |
| Amin, MCIM | 1 |
| Mishra, V | 1 |
| Agrawal, GP | 1 |
| Kesharwani, P | 1 |
| Chan, FK | 1 |
| Kyaw, M | 1 |
| Tanigawa, T | 1 |
| Higuchi, K | 1 |
| Fujimoto, K | 1 |
| Cheong, PK | 1 |
| Lee, V | 1 |
| Naito, Y | 1 |
| Watanabe, T | 1 |
| Ching, JY | 1 |
| Lam, K | 1 |
| Lo, A | 1 |
| Chan, H | 1 |
| Lui, R | 1 |
| Tang, RS | 1 |
| Sakata, Y | 1 |
| Tse, YK | 1 |
| Takeuchi, T | 1 |
| Handa, O | 1 |
| Nebiki, H | 1 |
| Wu, JC | 1 |
| Abe, T | 2 |
| Mishiro, T | 1 |
| Ng, SC | 1 |
| Arakawa, T | 1 |
| Dash, RP | 1 |
| Rais, R | 1 |
| Srinivas, NR | 1 |
| Hong, EJ | 1 |
| Park, DI | 1 |
| Oh, SJ | 1 |
| Song, MJ | 1 |
| Choi, WH | 1 |
| Hong, CH | 1 |
| Park, JH | 1 |
| Kim, HJ | 1 |
| Cho, YK | 1 |
| Shon, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Baldwin, CM | 1 |
| Keam, SJ | 1 |
| Jain, SC | 1 |
| Niwa, Y | 1 |
| Nakamura, M | 1 |
| Miyahara, R | 1 |
| Ohmiya, N | 1 |
| Watanabe, O | 1 |
| Ando, T | 1 |
| Kawashima, H | 1 |
| Itoh, A | 1 |
| Hirooka, Y | 1 |
| Goto, H | 1 |
| Lay, CS | 1 |
| Lin, CJ | 1 |
| Lin, JR | 1 |
| Vovolis, V | 1 |
| Christogianni, K | 1 |
| Koutsostathis, N | 1 |
| Zhang, L | 1 |
| Mei, Q | 1 |
| Li, QS | 1 |
| Hu, YM | 1 |
| Xu, JM | 1 |
| Luo, JC | 1 |
| Huang, KW | 1 |
| Leu, HB | 1 |
| Chen, LC | 1 |
| Hou, MC | 1 |
| Li, CP | 1 |
| Lu, CL | 1 |
| Lin, HC | 1 |
| Lee, FY | 1 |
| Lee, SD | 1 |
| Park, HG | 1 |
| Jung, MK | 1 |
| Jung, JT | 1 |
| Kwon, JG | 1 |
| Kim, EY | 1 |
| Seo, HE | 1 |
| Lee, JH | 1 |
| Yang, CH | 1 |
| Kim, ES | 1 |
| Cho, KB | 1 |
| Park, KS | 1 |
| Lee, SH | 2 |
| Kim, KO | 1 |
| Jeon, SW | 1 |
| Sanuki, T | 1 |
| Fujita, T | 1 |
| Kutsumi, H | 2 |
| Hayakumo, T | 2 |
| Yoshida, S | 1 |
| Inokuchi, H | 2 |
| Murakami, M | 1 |
| Matsubara, Y | 1 |
| Kuwayama, H | 3 |
| Kawai, T | 2 |
| Miyaji, H | 1 |
| Fujisawa, T | 1 |
| Terao, S | 1 |
| Yamazaki, Y | 1 |
| Azuma, T | 1 |
| Uotani, T | 1 |
| Sugimoto, M | 1 |
| Nishino, M | 1 |
| Kodaira, C | 1 |
| Yamade, M | 1 |
| Sahara, S | 1 |
| Yamada, T | 2 |
| Osawa, S | 1 |
| Sugimoto, K | 1 |
| Tanaka, T | 1 |
| Umemura, K | 1 |
| Watanabe, H | 1 |
| Miyajima, H | 1 |
| Furuta, T | 1 |
| Marelli, S | 1 |
| Pace, F | 1 |
| Inaba, T | 1 |
| Mizuno, M | 2 |
| Kawai, K | 2 |
| Yokota, K | 2 |
| Oguma, K | 2 |
| Miyoshi, M | 2 |
| Take, S | 1 |
| Okada, H | 2 |
| Tsuji, T | 2 |
| Vanderhoff, BT | 1 |
| Tahboub, RM | 1 |
| Johnson, M | 1 |
| Guilford, S | 1 |
| Libretto, SE | 1 |
| De Francesco, V | 4 |
| Faleo, D | 1 |
| Panella, C | 3 |
| Ierardi, E | 4 |
| Margiotta, M | 2 |
| Kawakami, K | 1 |
| Kudo, T | 1 |
| Ogiahara, S | 1 |
| Handa, Y | 1 |
| Moriyasu, F | 1 |
| Go, MF | 1 |
| Nemytin, IuV | 1 |
| Makarov, IuS | 1 |
| Pavlov, AI | 1 |
| Kashchenko, OI | 1 |
| Lezhenina, NP | 1 |
| Golochalova, TV | 1 |
| Kawabata, H | 1 |
| Habu, Y | 1 |
| Tomioka, H | 1 |
| Kobayashi, M | 1 |
| Oyasu, K | 1 |
| Mizuno, S | 1 |
| Kiyota, K | 1 |
| Nakajima, M | 1 |
| Kimoto, K | 1 |
| Miki, I | 1 |
| Aoyama, N | 2 |
| Sakai, T | 1 |
| Shirasaka, D | 1 |
| Wambura, CM | 1 |
| Maekawa, S | 1 |
| Kuroda, K | 1 |
| Tamura, T | 1 |
| Kita, T | 1 |
| Sakaeda, T | 1 |
| Okumura, K | 1 |
| Kasuga, M | 1 |
| Hawkey, CJ | 2 |
| Atherton, JC | 2 |
| Treichel, HC | 1 |
| Thjodleifsson, B | 2 |
| Ravic, M | 1 |
| Choi, BK | 1 |
| Yang, SY | 1 |
| Park, ET | 1 |
| Jang, YS | 1 |
| Lee, YJ | 1 |
| Seol, SY | 1 |
| Chung, JM | 1 |
| Luo, JY | 1 |
| Niu, CY | 1 |
| Wang, XQ | 1 |
| Zhu, YL | 1 |
| Gong, J | 1 |
| Gambaro, C | 1 |
| Bilardi, C | 1 |
| Dulbecco, P | 1 |
| Iiritano, E | 1 |
| Zentilin, P | 1 |
| Mansia, C | 1 |
| Usai, P | 1 |
| Vigneri, S | 1 |
| Savarino, V | 1 |
| Zullo, A | 3 |
| Marangi, S | 1 |
| Burattini, O | 1 |
| Berloco, P | 1 |
| Russo, F | 1 |
| Barone, M | 1 |
| Di Leo, A | 1 |
| Minenna, MF | 2 |
| Stoppino, V | 2 |
| Morini, S | 3 |
| Francavilla, A | 1 |
| Yang, KC | 1 |
| Wang, GM | 1 |
| Chen, JH | 1 |
| Chen, TJ | 1 |
| Lee, SC | 1 |
| Sharara, AI | 1 |
| Chaar, HF | 1 |
| Racoubian, E | 1 |
| Moukhachen, O | 1 |
| Barada, KA | 1 |
| Mourad, FH | 1 |
| Araj, GF | 1 |
| Hassan, C | 2 |
| Della Valle, N | 1 |
| Pietrini, L | 1 |
| Winn, S | 1 |
| Monno, R | 1 |
| de Korwin, JD | 1 |
| Ducrotté, P | 1 |
| Vallot, T | 1 |
| Horn, J | 1 |
| Miner, P | 1 |
| Isomoto, H | 1 |
| Furusu, H | 1 |
| Ohnita, K | 1 |
| Wen, CY | 1 |
| Inoue, K | 1 |
| Kohno, S | 1 |
| Lin, SR | 1 |
| Gatta, L | 1 |
| Ricci, C | 1 |
| Bernabucci, V | 1 |
| Cavina, M | 1 |
| Vaira, D | 1 |
| Calvet, X | 2 |
| Ducons, J | 1 |
| Bujanda, L | 1 |
| Bory, F | 1 |
| Montserrat, A | 1 |
| Gisbert, JP | 1 |
| Wang, F | 1 |
| Wang, XY | 1 |
| Jia, Y | 1 |
| Shen, SR | 1 |
| Xu, CX | 1 |
| Tang, WL | 1 |
| Liu, SJ | 1 |
| Chen, X | 1 |
| Gomollón, F | 1 |
| Murakami, K | 3 |
| Sato, R | 2 |
| Okimoto, T | 3 |
| Watanabe, K | 2 |
| Nasu, M | 1 |
| Fujioka, T | 4 |
| Kodama, M | 3 |
| Sato, S | 1 |
| Arita, T | 1 |
| Ji, S | 1 |
| Kim, HS | 1 |
| Jee, MK | 1 |
| Park, KW | 1 |
| Uh, Y | 1 |
| Lee, DK | 1 |
| Song, JS | 1 |
| Baik, SK | 1 |
| Kwon, SO | 1 |
| Asaka, M | 1 |
| Sugiyama, T | 1 |
| Fukuda, Y | 1 |
| Hirai, Y | 1 |
| Belousov, IuB | 1 |
| Karpov, OI | 1 |
| Belousov, DIu | 1 |
| Beketov, AS | 1 |
| Prakash, A | 1 |
| Faulds, D | 1 |
| Stack, WA | 1 |
| Knifton, A | 1 |
| Thirlwell, D | 1 |
| Cockayne, A | 1 |
| Jenkins, D | 1 |
| Dekkers, CP | 1 |
| Beker, JA | 1 |
| Gabryelewicz, A | 1 |
| Bell, NE | 1 |
| Humphries, TJ | 1 |
| Langtry, HD | 1 |
| Markham, A | 1 |
| Hizawa, K | 1 |
| Nakahara, T | 1 |
| Yano, Y | 1 |
| Inuzuka, S | 1 |
| Akagi, K | 1 |
| Matsumoto, T | 1 |
| Satoh, R | 1 |
| Kagawa, J | 1 |
| Lüth, S | 1 |
| Teyssen, S | 1 |
| Kölbel, CB | 1 |
| Singer, MV | 1 |
| Nagahara, A | 1 |
| Miwa, H | 1 |
| Ohkura, R | 1 |
| Sato, K | 1 |
| Hojo, M | 1 |
| Sato, N | 1 |
| Ishiki, K | 1 |
| Nagahara, Y | 1 |
| Maga, T | 1 |
| Torigoe, T | 1 |
| Nasu, J | 1 |
| Barth, J | 1 |
| Hahne, W | 1 |
| Fu, HY | 1 |
| Kawano, S | 1 |
| Tanimura, H | 1 |
| Takahashi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)[NCT01408186] | Phase 3 | 264 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Comparison of Ulcer Healing in Patients Taking Rabeprazole Plus Aspirin Versus Rabeprazole Plus Clopidogrel for Acute Peptic Ulcer[NCT01037491] | 200 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | |||
| Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics: Multicentre, Randomized, and Controlled Trials[NCT05861687] | Phase 2/Phase 3 | 51 participants (Actual) | Interventional | 2021-08-01 | Completed | ||
| Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection[NCT03124199] | Phase 3 | 40 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial[NCT00403364] | Phase 2/Phase 3 | 300 participants | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 100 |
Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 61 |
Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| with diarrhea | with metallic taste | headache | nausea | abdominal pain | |
| Rifaximin | 13 | 9 | 5 | 5 | 1 |
17 reviews available for rabeprazole and Peptic Ulcer
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Topics: Abdominal Injuries; Esomeprazole; Esophagitis, Peptic; Humans; Network Meta-Analysis; Peptic Ulcer; | 2022 |
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Topics: Abdominal Injuries; Esomeprazole; Esophagitis, Peptic; Humans; Network Meta-Analysis; Peptic Ulcer; | 2022 |
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Topics: Abdominal Injuries; Esomeprazole; Esophagitis, Peptic; Humans; Network Meta-Analysis; Peptic Ulcer; | 2022 |
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Topics: Abdominal Injuries; Esomeprazole; Esophagitis, Peptic; Humans; Network Meta-Analysis; Peptic Ulcer; | 2022 |
Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis.
Topics: Drug Therapy, Combination; Humans; Materia Medica; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2020 |
Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.
Topics: Animals; Drug Interactions; Gastroesophageal Reflux; Humans; Peptic Ulcer; Proton Pump Inhibitors; R | 2018 |
Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Gastric Acid; Gastroesophagea | 2009 |
Rabeprazole for the treatment of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Enzyme Inhibitors; Gastroesophageal Refl | 2012 |
Treatment and management of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2002 |
[New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazole | 2004 |
Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2004 |
Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastric Aci | 2004 |
What is potent acid inhibition, and how can it be achieved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2005 |
Rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1998 |
Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1999 |
[Selection of antibiotics and planning of eradication for H. pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Administr | 2001 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2002 |
[Dual therapy for Helicobacter pylori resistance to anti microbial agents].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trial | 2002 |
[Continuation of acid suppression therapy after H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Clinical Trials as Topic; Enzyme | 2002 |
34 trials available for rabeprazole and Peptic Ulcer
| Article | Year |
|---|---|
Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2013 |
Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Famotidine; Female; Hemoglobins; Histamine H2 | 2017 |
A postmarketing surveillance study of dexrabeprazole in the treatment of acid peptic disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; | 2009 |
Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 2009 |
The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2010 |
Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Clopid | 2011 |
Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2012 |
Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; | 2012 |
Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; As | 2012 |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 2002 |
Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Chi-Square | 2002 |
[Antisecretory effect of losec and pariet in peptic ulcer therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric A | 2002 |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Be | 2003 |
[A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Alkalies; Anti-Ulcer Agents; B | 2003 |
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Ag | 2003 |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2003 |
Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2004 |
Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
[The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
[Five-day rabeprazole-based triple therapy for helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Drug Administrati | 2004 |
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2006 |
Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cy | 2006 |
Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2007 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2008 |
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy | 1998 |
Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1999 |
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2001 |
14 other studies available for rabeprazole and Peptic Ulcer
| Article | Year |
|---|---|
Rabeprazole Coadministration Controls Ulcer Recurrence in Patients on Low-dose Aspirin Therapy: A Multicenter Prospective Study.
Topics: Anti-Ulcer Agents; Aspirin; Humans; Peptic Ulcer; Prospective Studies; Rabeprazole; Ulcer | 2023 |
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2020 |
The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cohort Studies; Drug Ther | 2014 |
Stomach specific polymeric low density microballoons as a vector for extended delivery of rabeprazole and amoxicillin for treatment of peptic ulcer.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Delivery Systems; Drug Liberati | 2016 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2008 |
Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithr | 2010 |
Immunoglobulin E-mediated anaphylaxis to rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anaphylaxis; Angioedema; Dimethindene; Drug Hypersens | 2010 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesop | 2002 |
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
[Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Th | 2007 |
Effect of amoxicillin, clarithromycin, and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2000 |
4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |